Quotient Clinical, the translational pharmaceutics company, has expanded its data sciences services in response to increasing customer demand, doubling the footprint of its facilities in Edinburgh and Nottingham, as well as increasing its specialist headcount and appointing a new Vice President.
Data sciences is an integral part of the company’s service, delivering real-time data to customers for review and interpretation, enabling crucial dosing decisions to be made during the course of a study. Greg Johnson, the new Vice President of Data Sciences, joined Quotient in March 2015 and has more than 25 years of industry experience of directing biometrics and data sciences in large contract research organizations.
Mark Egerton, CEO of Quotient Clinical, said: “Greg brings a wealth of industry experience that will be invaluable as we grow our data sciences offering. Demand for these services is rapidly increasing, and we are now undertaking electronic data capture, data management, pharmacokinetics, modelling and simulation, biostatistics and reporting on more than 80% of our customer programmes, compared with just 50% a few years ago.”
Greg Johnson, the new Vice President of Data Sciences, added: “Translational Pharmaceutics can have a profound impact on reducing development timelines and associated costs, and this is driving an increase in demand for all our services. I look forward to leading the growth of our data sciences capabilities, ensuring that we deliver integrated solutions for our customers.”